Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The reporting period covers the month of March 2026, with the specific transaction date being March 2, 2026. The filing details a share repurchase executed as part of an existing buyback programme under a non-discretionary agreement with BNP Paribas SA.
Key Financial Metrics
The filing focuses exclusively on capital structure and share repurchase activity. It does not contain operational financial data such as revenue, profit, cash flow, or margins.
- Shares Purchased (March 2, 2026): 500,000 ordinary shares.
- Price Range: Lowest price paid was 2,168.00 GBp; highest price paid was 2,195.00 GBp.
- Volume-Weighted Average Price (VWAP): 2,180.14 GBp.
- Total Buyback Activity (Since Feb 17, 2026): 4,636,000 ordinary shares purchased.
- Treasury Shares Held: 244,527,094 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,071,635,394 ordinary shares.
- Treasury Voting Rights: 6.01% of total voting rights.
Material Changes
The primary material change is the reduction of shares in issue and the increase in treasury shares following the repurchase of 500,000 shares on March 2, 2026. This transaction is a continuation of the buyback programme announced on February 17, 2026. The filing does not provide comparative financial performance data against prior periods.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024 and Q4 Results for 2025. No specific new risks or contingencies are detailed in this document.
Investor Verification Checklist
- Verify the total remaining authorization under the existing buyback programme announced on February 17, 2026.
- Confirm the impact of the 6.01% treasury shareholding on earnings per share (EPS) calculations.
- Review the "Risk Factors" in the 2024 Form 20-F and 2025 Q4 results for context on the company's broader financial health, as this filing contains no operational metrics.
- Monitor subsequent filings for updates on the completion status of the non-discretionary buyback agreement.